Kranthi M. Panth

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Author Correction: Near-infrared fatty acid molecular probe for image-guided surgery of glioblastoma.

Author Correction: Near-infrared fatty acid molecular probe for image-guided surgery of glioblastoma.

Journal: Npj imaging
Published: July 15, 2026

Near-infrared fatty acid molecular probe for image-guided surgery of glioblastoma.

Near-infrared fatty acid molecular probe for image-guided surgery of glioblastoma.

Journal: Npj imaging
Published: October 09, 2024

Pre-transplant kidney quality evaluation using photoacoustic imaging during normothermic machine perfusion.

Pre-transplant kidney quality evaluation using photoacoustic imaging during normothermic machine perfusion.

Journal: Photoacoustics
Published: September 20, 2023

Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain.

Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain.

Journal: Cancers
Published: December 10, 2021

In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors.

In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors.

Journal: Contrast media & molecular imaging
Published: October 15, 2021

Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules.

Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules.

Journal: EJNMMI research
Published: March 03, 2021

In Vivo Evaluation of Indium-111-Labeled 800CW as a Necrosis-Avid Contrast Agent.

In Vivo Evaluation of Indium-111-Labeled 800CW as a Necrosis-Avid Contrast Agent.

Journal: Molecular imaging and biology
Published: June 10, 2020

A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.

A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.

Journal: BMC cancer
Published: January 15, 2016

In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity.

In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity.

Journal: Scientific reports
Published: October 22, 2015

Decision support systems for personalized and participative radiation oncology.

Decision support systems for personalized and participative radiation oncology.

Journal: Advanced drug delivery reviews
Published: September 15, 2015

New ways to image and target tumour hypoxia and its molecular responses.

New ways to image and target tumour hypoxia and its molecular responses.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: July 07, 2015

Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells.

Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: April 17, 2015
Showing 1-12 of 12

Last Updated: 09/26/2026